New Myositis Classification Criteria—What We Have Learned Since Bohan and Peter

Valérie Leclair1 · Ingrid E. Lundberg2

Published online: 17 March 2018
© The Author(s) 2018. This article is an open access publication

Abstract

Purpose of Review Idiopathic inflammatory myopathy (IIM) classification criteria have been a subject of debate for many decades. Despite several limitations, the Bohan and Peter criteria are still widely used. The aim of this review is to discuss the evolution of IIM classification criteria.

Recent Findings New IIM classification criteria are periodically proposed. The discovery of myositis-specific and myositis-associated autoantibodies led to the development of clinico-serological criteria, while in-depth description of IIM morphological features improved histopathology-based criteria. The long-awaited European League Against Rheumatism and American College of Rheumatology (EULAR/ACR) IIM classification criteria were recently published.

Summary The Bohan and Peter criteria are outdated and validated classification criteria are necessary to improve research in IIM. The new EULAR/ACR IIM classification criteria are thus a definite improvement and an important step forward in the field.

Keywords Classification criteria · Inflammatory myopathy · Dermatomyositis · Polymyositis · Inclusion body myositis

Introduction

Classification criteria are meant to identify uniform and comparable groups of subjects for research purposes. In an era where international collaborations are frequent and, more than ever, needed to advance research in rare autoimmune diseases, agreement on a common set of classification criteria is critical. In 1975, Dr. Anthony Bohan and Dr. James B. Peter provided a first set of classification criteria that enabled the inflammatory idiopathic myopathy (IIM) field to evolve tremendously. They divided the IIMs into five groups: primary idiopathic polymyositis (PM), primary idiopathic dermatomyositis (DM), DM/PM associated with neoplasia, childhood DM/PM associated with vasculitis, and DM/PM with associated collagen-vascular disease [1, 2]. In the following decades, the description of new clinical subsets and a deeper understanding of IIM pathophysiology forced the myositis community to rethink and modify those criteria. Classification is not just a question of semantics [3–6], as aggregation of IIM heterogeneous subsets with different underlying molecular mechanisms likely contributes to the challenge in obtaining positive outcomes in clinical trials. An adequate IIM classification would hopefully translate in improved IIM management and outcomes. In this review, we will discuss the evolution of classification criteria since the original Bohan and Peter criteria. We will also review the recently published European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) classification criteria for adult and juvenile IIM [7].

Classification Criteria in IIM—a Brief History

From 1975 to 2000

In 1975, the original Bohan and Peter classification proposal for both diagnosis and classification was published and remains to this day the most widely used classification criteria.
involvement, and the aforementioned typical histologic slowly progressive course, a specific pattern of muscle distinctive clinical and laboratory features including a sion body myositis (IBM) [11, 12]. This subset showed position on histopathology was described and named inclu-
treatment with specific tubulofilament and amyloid depo-
lished, a new subset of myositis resistant to corticosteroid

Subsequent studies reported that the Bohan and Peter criteria
tain exclusion criteria to eliminate IIM mimickers were pro-
diagnosis for each subset were proposed and importantly cer-

Despite these novelties, the Bohan and Peter criteria
clear definitions of the classical DM skin rashes,
dermatomyositis features (i.e., myopathic electromyography), vague exclusion
criteria, unclear definitions of the classical DM skin rashes,
and for not specifying the exact number of features necessary
to fulfill certain specific criteria (i.e., muscle biopsy). In 1977,
the criteria were applied to a case series of 153 IIM subjects,
but the absence of a control group precluded the authors to
come on the ability of their criteria to discriminate DM/
PM from mimickers such as neuromuscular conditions [8].
Subsequent studies reported that the Bohan and Peter criteria
could adequately distinguish DM/PM from systemic lupus
erthematous (SLE) and systemic sclerosis (SSc) [9]. Their
combined sensitivity for definite and probable DM/PM diag-
nosis in 885 patients in studies published from 1977 to 1993
ranged between 74 and 100% [10].

At the time the Bohan and Peter criteria were pub-
ished, a new subset of myositis resistant to corticosteroid
treatment with specific tubulofilament and amyloid depo-
sition on histopathology was described and named inclu-
sion body myositis (IBM) [11, 12]. This subset showed
distinctive clinical and laboratory features including a slowly progressive course, a specific pattern of muscle involvement, and the aforementioned typical histologic findings. This new entity was incorporated in the IIM
diagnostic criteria formulated by Dalakas in 1991 [13].
These criteria, based on expert opinion, provided more
detailed descriptions of each criterion of the Bohan and
Peter criteria, including the histopathologic features ex-
pected to be found in DM, PM, or sporadic IBM
(sIBM). Accordingly, perifascicular atrophy was consid-
ered diagnostic of DM especially if coupled with
perivascular inflammatory infiltrates. Endomysial inflam-
mation surrounding or invading non-necrotic muscle fibers
without rimmed vacuoles and eosinophilic cytoplasmic
inclusions was characteristic of PM.

While some investigators focused their efforts on linking
histopathologic changes associated with each IIM subset to
underlying pathologic mechanisms, others were discovering
and describing myositis-specific autoantibodies (MSA). By
1990, seven MSA targeting different cytoplasmic ribonucleo-
proteins including helicase protein (Mi2), signal recognition
particle (SRP), and five anti-ribonucleic RNA synthetases
(histidyl (Jo1), threonyl (PL-7), alanayl (PL-12), glycylic (EJ),
and isoleucyl (OJ)) were discovered and each one was found
to be associated with unique clinical features [14, 15••]. In
1991, Love et al. proposed a novel classification of IIM based
on these MSA, subsequent to a cross-sectional analysis of 212
IIM patients [16]. For each MSA subgroup, they detailed dif-
derent disease profiles in terms of clinical features, human
leucocyte antigen (HLA) associations, and prognosis. The
“anti-synthetase syndrome” which refers to the association
of interstitial lung disease (ILD), fever, arthritis, mechanic’s
hand, myositis, and anti-synthetase autoantibody positivity
was well-described, along with the anti-Mi2 phenotype of
DM with classical rashes and good response to steroids.

In 1995, Tanimoto et al. published a new set of nine
criteria to classify patients as either DM or PM based on a
multicenter retrospective study with questionnaires and
chart review [17]. Four of these criteria were not included
in the original Bohan and Peter criteria: (1) muscle pain on
graping or spontaneous muscle pain; (2) non-destructive
arthritis or arthralgias; (3) signs of systemic inflamma-
tion—fever, elevated C-reactive protein, or erythocyte sed-
imentation rate; and (4) the presence of anti-Jo1 antibody.
Except for the latter, these new criteria were non-specific
for IIM and several subsets such as juvenile IIM, cancer-
associated myositis, and sIBM were not included in the
analysis. A few years later, Targoff et al. proposed new
modifications to the Bohan and Peter criteria with the goal
of increasing the specificity of the original criteria which incorporated all the known MSAs at the time and muscle
magnetic resonance imaging (MRI) [10]. sIBM was includ-
ed in their IIM subsets as defined by the diagnostic criteria
published by Griggs et al. that require specific clinical fea-
tures and the presence on muscle biopsy of (1) inflamma-
tion, (2) vacuoles, and (3) amyloid deposits or
tubulofilament by electron microscopy [18].

### Table 1

| The Bohan and Peter criteria for DM and PM [1, 2] |
|--------------------------------------------------|
| First, rule out all other forms of myopathies |
| 1. Symmetrical weakness, usually progressive, of the limb-girdle muscles with or without dysphagia and respiratory muscle weakness |
| 2. Muscle biopsy evidence of myositis |
| - Necrosis of type I and type II muscle fibers; phagocytosis, degeneration, and regeneration of myofibers with variation in myofiber size; endomysial, perimysial, perivascular, or interstitial mononuclear cells. |
| 3. Elevation of serum levels of muscle-associated enzymes (CK, LDH, transaminases, aldolase) |
| 4. EMG triad of myopathy |
| - a. Short, small, low-amplitude polyphasic motor unit potentials |
| - b. Fibrillation potentials, even at rest |
| - c. Bizarre, high-frequency repetitive discharges |
| 5. Characteristic rashes of dermatomyositis |
| Definite PM: all first four elements, probable PM: 3 of first 4, possible PM: 2 of first 4. |
| Definite DM: rash plus 3 others, probable DM: rash plus 2 others, possible DM: rash plus 1 other |

CK, creatinine kinase; LDH, lactate dehydrogenase; EMG, electromyography; PM, polymyositis; DM, dermatomyositis

in the field of IIM (Table 1). For the first time, DM and PM were differentiated by the presence of classical DM skin rashes, definitions for “definite,” “probable,” and “possible” diagnosis for each subset were proposed and importantly certain exclusion criteria to eliminate IIM mimickers were provided. Despite these novelties, the Bohan and Peter criteria were criticized for including several non-specific myositis features (i.e., myopathic electromyography), vague exclusion criteria, unclear definitions of the classical DM skin rashes, and for not specifying the exact number of features necessary to fulfill certain specific criteria (i.e., muscle biopsy). In 1977, the criteria were applied to a case series of 153 IIM subjects, but the absence of a control group precluded the authors to comment on the ability of their criteria to discriminate DM/PM from mimickers such as neuromuscular conditions [8].

Subsequent studies reported that the Bohan and Peter criteria could adequately distinguish DM/PM from systemic lupus erythematosus (SLE) and systemic sclerosis (SSc) [9]. Their combined sensitivity for definite and probable DM/PM diagnosis in 885 patients in studies published from 1977 to 1993 ranged between 74 and 100% [10].

At the time the Bohan and Peter criteria were published, a new subset of myositis resistant to corticosteroid treatment with specific tubulofilament and amyloid deposition on histopathology was described and named inclusion body myositis (IBM) [11, 12]. This subset showed distinctive clinical and laboratory features including a slowly progressive course, a specific pattern of muscle involvement, and the aforementioned typical histologic findings. This new entity was incorporated in the IIM
From 2000 up to Now

For decades, clinicians, especially dermatologists, recognized an entity called DM sine myositis or amyopathic DM [19] that refers to subjects with DM rashes without evidence of muscle involvement. In 2002, Sontheimer wrote an editorial proposing the expansion of the DM spectrum to include hypomyopathic and amyopathic dermatomyositis (ADM) [20]. ADM was integrated in the 2003 revised Dalakas diagnostic criteria but since it allowed “subclinical myopathy” on investigations, ADM more closely met the definition of hypomyopathic DM introduced by Sontheimer [21]. Van der Meulen et al. emphasized the importance of histopathologic assessment in identifying IIM subsets and raised the risk of misclassification of sIBM cases as PM by previous classification criteria [22]. Their paper fueled discussions among IIM experts who questioned the currently accepted definition of PM [22–26].

The European Neuromuscular Center (ENMC) criteria designed on behalf of the Muscle Study Group and published in 2004 also required histopathologic confirmation in conjunction with clinical and laboratory criteria for IIM classification. These detailed criteria include MRI findings, some MSA, and specific immunohistochemical stainings that help differentiate DM and PM such as major histocompatibility complex class 1 specific immunohistochemical stainings that help differentiate DM introduced by Sontheimer [21]. Van der Meulen et al. emphasized the importance of histopathologic assessment in identifying IIM subsets and raised the risk of misclassification of sIBM cases as PM by previous classification criteria [22]. Their paper fueled discussions among IIM experts who questioned the currently accepted definition of PM [22–26].

The European Neuromuscular Center (ENMC) criteria designed on behalf of the Muscle Study Group and published in 2004 also required histopathologic confirmation in conjunction with clinical and laboratory criteria for IIM classification. These detailed criteria include MRI findings, some MSA, and specific immunohistochemical stainings that help differentiate DM and PM such as major histocompatibility complex class 1 (MHC-1) and membrane attack complex (MAC) [27–29]. They delineate seven IIM subsets: IBM, PM, DM, ADM, possible DM sine dermatitis, non-specific myositis, and immune-mediated necrotizing myopathy (IMNM). The IMNM subset is differentiated by histopathologic features where muscle necrosis predominates with only sparse or mild perivascular inflammatory cells and possible vascular MAC deposition. The “non-specific myositis” refers to a subset of IIM that lacks the characteristic histopathologic changes of DM, PM, or IMNM, but still presents with perivascular or perimysial inflammatory cell infiltrates or scattered endomysial CD8+ T cells not clearly surrounding or invading muscle fibers. The authors believe that these different histopathology-oriented approaches to classification better reflect the underlying pathogenic insults, suggesting DM to be a B cell-mediated microangiopathy and PM a result of a MHC-1 restricted cytotoxic T cell response. In 2011, Pestronk challenged this hypothesis and introduced a very detailed classification of myopathology for IIM based on expert opinion, setting aside the previous DM, PM, and sIBM nomenclature [30]. The six patterns constituting Pestronk’s classification are immune myopathy with perimysial pathology (IMPP), myovasculopathy, immune polymyopathy, IIM with endomysial pathology (IIM-EP), histiocytic inflammatory myopathy, and inflammatory myopathy with vacuoles, aggregates, and mitochondrial pathology (IM-VAMP). Under that classification model, a DM patient could be classified either in the IMPP or myovasculopathy group, depending on the morphological features on muscle biopsy. This proposed classification was not validated and, although histopathological features are specific for different subtypes of IIM, some IIM patients will not be classified as such because they present with limited, unspecific, or overlapping histopathological features, giving histopathology-based criteria a low sensitivity. Furthermore, histopathological features may change over time and could reflect disease duration more than clinical phenotypes in some cases.

In the first decade of the twenty-first century, several new MSAs were described including three new anti-aminoacyl-tRNA synthetases (asparaginyl (KS), tyrosyl (HA), phenylalanyl (Zo)), the anti-melanoma differentiation antigen 5 (anti-MDA5), the anti-small ubiquitin-like modifier activating enzyme (anti-SAE), the anti-transcriptional intermediary factor 1 (anti-TIF1), the anti-antinuclear matrix protein (anti-NXP-2), and the anti-3-hydroxy-3-methylglutaryl coenzyme A reductase (anti-HMGCR). Some of those autoantibodies have been linked to specific phenotypes and clinical courses such as the anti-TIF1γ, strongly associated with cancer-associated DM, or anti-HMGCR, a marker of IMNM associated with statin use [31–33]. MSAs and their role in IIM are ever-evolving topics and have been previously reviewed extensively elsewhere [14, 34–36].

In 2005, Troyanov et al. approached IIM classification from a different perspective, merging IIM clinical features with MSAs and myositis-associated autoantibodies profiles [37]. They considered overlap features, such as arthritis, ILD, or Raynaud phenomenon, as central components of their classification scheme. Their initial clinico-serological classification included four subsets: overlap myositis (OM), pure DM, pure PM, and cancer-associated myositis. The OM subset is characterized by the presence of autoantibodies such as anti-synthetases, SSc-associated autoantibodies, anti-SRP, and/or overlap features. Pure DM refers to the presence of a DM rash and/or positivity for anti-Mi2, and pure PM includes patients without overlap features or autoantibodies. Using this purely clinical approach, OM was the most frequent subset in the 100 IIM subjects included in their study. This subgroup also showed good response to corticosteroids. This clinico-serological classification was correlated with the muscle biopsies of 178 IIM patients based on the ENMC histopathologic criteria, and both approaches were found to be complementary [38••]. This classification was later updated by the authors to integrate newly described MSAs such as anti-MDA5, and more subsets namely overlap myositis with DM features (OMDM), necrotizing autoimmune myositis (NAM), and sIBM. Nailfold capillaroscopy abnormalities were also introduced as a characteristic feature of DM and OM [39••, 40]. In 2016, Benveniste et al. outlined a classification scheme integrating clinical and pathological features with four IIM subsets (IBM, OM, IMNM, and DM) and subdivision by MSA status [15••]. This interesting classification that bears similarities with the clinico-serological approach...
proposed by Troyanov et al. is however based on expert opinions and requires further validation.

**The EULAR/ACR Classification Criteria**

IIM classification has been a matter of debate for decades, and myositis experts agree on the importance of reaching a consensus to improve future clinical trials. The previous classification criteria were mainly empirically derived and not properly validated. When studies were based on patient’s data, patient cohorts were often small, single-center, and did not include controls. To palliate for this, a group of international IIM experts including adult and pediatric rheumatologists, neurologists, dermatologists, epidemiologists, and biostatisticians was assembled in 2004 to develop new IIM classification criteria following the recommendations published by the EULAR/ACR [3, 4]. The goal was the development of classification criteria that would distinguish IIMs from mimickers and categorize IIMs in major subgroups with a minimum of clinical and readily available laboratory features. A consensus method was used for study design, definition of possible criteria candidates, and selection of IIM subgroups and comparators. Ninety-three variables were identified, selected from both previous criteria and suggestions of experts, and applied to 976 IIM cases and 624 non-IIM cases from 47 centers across the world. Two models, with or without muscle biopsy results, were developed to better reflect some clinical settings such as pediatrics, where performing muscle biopsy is not standard of care. Based on a complex but robust method, 16 variables deemed to provide better discrimination for IIM cases were weighted and included in a final criteria set presented in Table 2 and Fig. 1. A web-based calculator provides a score that represents the probability of a particular individual to have an IIM. Thus, researchers using this classification retain the capability to tailor the inclusion criteria to a certain level of sensitivity or specificity depending on the type of study considered. It provides detailed definition for each criteria and showed a sensitivity and specificity for a probable

| Variable | Score No muscle biopsy | Score With muscle biopsy |
|----------|------------------------|--------------------------|
| Age of onset of first symptom assumed to be related to the disease ≥ 18 and < 40 years | 1.3 | 1.5 |
| Age of onset of first symptom assumed to be related to the disease ≥ 40 years | 2.1 | 2.2 |
| Muscle weakness | | |
| Objective symmetric weakness, usually progressive, of the proximal upper extremities | 0.7 | 0.7 |
| Objective symmetric weakness, usually progressive, of the proximal lower extremities | 0.8 | 0.5 |
| Neck flexors are relatively weaker than neck extensors | 1.9 | 1.6 |
| In the legs, proximal muscles are relatively weaker than distal muscles | 0.9 | 1.2 |
| Skin manifestations | | |
| Heliotrope rash | 3.1 | 3.2 |
| Gottron’s papules | 2.1 | 2.7 |
| Gottron’s sign | 3.3 | 3.7 |
| Other clinical manifestations | | |
| Dysphagia or esophageal dysmotility | 0.7 | 0.6 |
| Laboratory measurements | | |
| Anti-Jo1 autoantibody present | 3.9 | 3.8 |
| Elevated serum levels of CK or LDH or ASAT/AST/SGOT or ALAT/ALT/SGPT | 1.3 | 1.4 |
| Muscle biopsy features—presence of: | | |
| Endomysial infiltration of mononuclear cells surrounding, but not invading, myofibres | 1.7 | |
| Perimysial and/or perivascular infiltration of mononuclear cells | 1.2 | |
| Perifascicular atrophy | 1.9 | |
| Rimmed vacuoles | 3.1 | |

Modified from [7]

Anti-Jo1, anti-histidyl-tRNA synthetase; CK, creatine kinase; LDH, lactate dehydrogenase; ASAT/AST/SGOT, aspartate aminotransferase; ALAT/ALT/SGPT, alanine aminotransferase
Table 3  Comparison of various classification and diagnostic criteria sets

| Type of criteria          | SNa (%) | SPa (%) | Type of classification | IIM subtypes proposed                                                                 |
|---------------------------|---------|---------|------------------------|----------------------------------------------------------------------------------------|
| Bohan and Peter [1, 2]    | 94–98   | 29–55   | Diagnostic/classification | DM, PM, Childhood DM/PM with vasculitis DM/PM with neoplasia or CTD.                   |
| Tanimoto [17]             | 89–96   | 29–31   | Classification         | DM, PM                                                                                 |
| Targoff [10]              | 97–93   | 29–89   | Diagnostic/classification | DM, PM, Childhood DM/PM with vasculitis DM/PM with neoplasia or CTD IBM                |
| Dalakas [21]              | 6–77    | 99      | Diagnostic             | DM, PM, ADM                                                                            |
| ENMC [27]                 | 52–71   | 82–97   | Classification         | DM, PM, ADM DM sine dermatitis Non-specific myositis IMNM IBM                            |
| EULAR/ACR [7]             | No biopsy |        | Classification         | Xb, X, DM, PM, ADM JDM, juvenile dermatomyositis                                         |

SN, sensitivity; SP, specificity; EMG, electromyography; BX, muscle biopsy; MSA, myositis-specific autoantibodies; MRI, magnetic resonance imaging; DM, dermatomyositis; PM, polymyositis; ADM, amyopathic dermatomyositis; CTD, connective tissue disease; IBM, sporadic inclusion body myositis; IMNM, immune-mediated necrotizing myopathy; JDM, juvenile dermatomyositis

a “Definite” and “probable” diagnoses were considered positive cases, and “possible” diagnoses, negative cases. Specialist diagnosis represented the gold standard [7, 41].

b The EULAR/ACR classification can be used with or without muscle biopsy results.
IIM diagnosis of 93 and 88%, respectively, when biopsy results are included (Table 3) [7, 41]. As with any classification schema, the EULAR/ACR model presents limitations. IIM being a heterogeneous group of diseases, not enough patients from rare subgroups (e.g., IMNM, hypomyopathic DM, and juvenile PM) could be recruited and only one MSA, anti-Jo1, was documented in enough subjects to be included in the final variables. It is plausible that with wider use of myositis antibodies, anti-Jo1 could be replaced by any MSA. Muscle MRI, only available in 38% of cases, was also excluded from the analysis. Thus, these criteria will soon require revision using a cohort with further data on MSAs and MRI, as well as validation in an external cohort with IIM cases and comparators.

**Discussion**

Classification of IIM has been and will likely remain the topic of much discussion and debate. Attempts at categorizing a heterogeneous group of diseases with multiple possible organ involvement, considerable overlapping features, and different underlying pathologic molecular mechanisms that are yet to be fully deciphered are a daunting task. In addition, some IIM subsets such as sIBM are characterized by an insidious onset with characteristic histologic findings appearing late in the disease course, which may lead to misclassification of affected patients as PM in the early phase of their disease [42]. More clinical sIBM diagnostic criteria have been recently proposed to address this issue [43, 44]. Certain subsets of the IIM disease spectrum can be dominated by extra-muscular features with no or mild muscle weakness which presents yet another challenge for IIM classification. The anti-synthetase syndrome which encompasses a large spectrum of clinical presentations influenced, at least in part, by the detected anti-synthetase autoantibody is a good example of this [45–47]. According to the new EULAR/ACR criteria, this subset still falls in the PM category, which may seem outdated given the subset’s known distinct phenotype and clinical course [48, 49]. In that regard, a clinical-serological approach seems better suited.

A careful evaluation of the clinical features of IIM including muscle weakness pattern is also central to classification in a research setting. When assessing muscle weakness, clinicians should be aware of the caveats of frequently used tools, such as the ceiling effect of the MMT8 [50]. As diagnostic methods are constantly evolving, classification criteria need to be periodically reviewed to leverage new diagnostic capabilities. Muscle MRI has been incorporated in some of the recent criteria set. This technique allows for assessment of muscular inflammation in terms of extent and localization [51–53]. Atrophy and fatty replacement of muscle tissue, a reflection of disease damage, can also be assessed. However, muscle MRI findings are not specific for IIM and intramuscular edema can be found in several other disorders including trauma, myonecrosis, infection, rhabdomyolysis, and non-inflammatory myopathies [53]. Accessibility might be an issue with this imaging technique, which can also be the case of MSA detection, even in this era of commercial MSA assay availability. One also needs to keep in mind that individual MSA have a low sensitivity for IIM, although collectively their sensitivity may reach 60–70%, and therefore their absence do not exclude an IIM diagnosis [54]. On the other hand, the presence of MSA provides precious insights to clinicians as previously stated, and future large-scale epidemiologic studies will certainly help integrate MSA in a valid classification scheme. Of note, even if EMG results were excluded from new EULAR/ACR criteria, this technique retains an important adjunct to IIM diagnosis and should be ordered especially in cases where an alternate neuromuscular diagnosis is suspected. As suggested by Troyanov et al., nailfold capillaroscopy is also a safe, non-invasive procedure that provides valuable information to the clinician. However, the ability of capillaroscopy to discriminate DM and PM cases, which are frequently merged together in studies, has yet to be established, and its’ evaluation and interpretation are not standardized [55]. Whether the new 2017 EULAR/ACR classification criteria for myositis will be useful to identify patients with shared molecular pathophysiology has still to be tested.

**Conclusions**

Over the years, many IIM experts have offered invaluable contributions to our knowledge of the IIM disease spectrum and have proposed various approaches to its classification. Bohan and Peter criteria continue to be used widely in medical schools and residency programs and still provide deep understanding of IIM to the trainees. In the hope of transitioning to a more contemporary classification, the EULAR/ACR criteria have been developed and validated with a robust methodology, an improvement over previous criteria sets. The new IIM classification criteria are a valuable addition to the myositis disease activity core measures endorsed by IMACS and the recently published ACR/EULAR adult PM/DM and juvenile DM response criteria [50, 56, 57, 58]. In the future, these new classification and response criteria should continue to evolve and reflect epidemiologic and molecular knowledge advances on IIM. Future clinical trials are expected to use these new criteria hopefully leading to novel therapeutics in myositis.

**Funding Information** Dr. Leclair is funded by the Visithan-Khy Award from l’Association des Médecins Rhumatologues du Québec and the Jewish General Hospital Department of Medecine Foundation Fund. Dr. Lundberg has funding from the Swedish Research Council GRANT K2014-52X-14045-14-3, Swedish Rheumatism Association, King Gustaf V 80-year Foundation, the Rheumatism Association, Konung Gustaf V:s och Drottning Victorias Frimurarstiftelse, and the
regional agreement on medical training and clinical research between Stockholm County Council.

Compliance with Ethical Standards

Conflict of Interest  Dr. Lundberg has received research grants from Bristol-Myers Squibb and from AstraZeneca and has served on advisory boards for Bristol-Myers Squibb and MedImmune.

Dr. Leclair declares that she has no conflicts of interest.

Human and Animal Rights and Informed Consent  This article does not contain any studies with human or animal subjects performed by any of the authors.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

Papers of particular interest, published recently, have been highlighted as:

• Of importance
• Of major importance

1. Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med. 1975;292(8):403–7.
2. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975;292(7):344–7.
3. Singh JA, Solomon DH, Dougados M, Felson D, Hawker G, Katz P, et al. Development of classification and response criteria for rheumatic diseases: why and how? Arthritis Rheum. 2006;55(3):348–52.
4. Dougados M, Gossec L. Classification criteria for rheumatic diseases: a review of methodologic properties. Arthritis Rheum. 2007;57(7):1112–5.
5. Johnson SR, Gock ON, Singh-Grewal D, Vlad SC, Feldman BM, Felson DT, et al. Classification criteria in rheumatic diseases: a review of methodologic properties. Arthritis Rheum. 2007;57(7):1119–33.
6. Aggarwal R, Ringold S, Khanna D, Neogi T, Johnson SR, Miller A, et al. Distinctions between diagnostic and classification criteria? Arthritis Care Res (Hoboken). 2015;67(7):891–7.
7. Lundberg IE, Tjarnlund A, Bottai M, Werth VP, Pilkington C, Visser M, et al. European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis. 2017;76(12):1955–64. The new classification criteria for myositis are data driven, were developed in an international multidisciplinary collaboration and are based on a probability model. The variables are given different scores and the probability model gives a flexibility in number of variables needed to be tested to define a case as myositis and a subgroup of myositis.
8. Bohan A, Peter JB, Bowman RL, Pearson CM. Computer-assisted analysis of 153 patients with polymyositis and dermatomyositis. Medicine (Baltimore). 1977;56(4):255–86.
9. Oddis CV, Medsger TA, J. Inflammatory myopathies. Baillieres Clin Rheumatol. 1995;9(3):497–514.
10. Targoff IN, Miller FW, Medsger TA Jr, Oddis CV. Classification criteria for the idiopathic inflammatory myopathies. Curr Opin Rheumatol. 1997(9)(6):527–35.
11. Yunis EJ, Samaha FJ. Inclusion body myositis. Lab Investig. 1971;25(3):240–8.
12. Carpenter S, Karpati G, Heller I, Eisen A. Inclusion body myositis: a distinct variety of idiopathic inflammatory myopathy. Neurology. 1978;28(1):8–17.
13. Dalakas MP, Polymyositis, dermatomyositis and inclusion-body myositis. N Engl J Med. 1991;325(21):1487–98.
14. Satoh M, Tanaka S, Ceribelli A, Calise SJ, Chan EK. A comprehensive overview on myositis-specific antibodies: new and old biomarkers in idiopathic inflammatory myopathy. Clin Rev Allergy Immunol. 2017;52(1):1–19.
15. Benveniste O, Stenzel W, Allenbach Y. Advances in serological diagnostics of inflammatory myopathies. Curr Opin Neurol. 2016;29(5):662–73. The authors propose a novel clinico-serological classification with emphasis on MSA and MAA statuses.
16. Love LA, Leff RL, Fraser DD, Targoff IN, Dalakas M, Plotz PH, et al. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define homogeneous patient groups. Medicine (Baltimore). 1991;70(6):360–74.
17. Tanimoto K, Nakano K, Kano S, Mori S, Ueki H, Nishitani H, et al. Classification criteria for polymyositis and dermatomyositis. J Rheumatol. 1995;22(4):668–74.
18. Griggs RC, Askanas V, DiMauro S, Engel A, Karpati G, Mendell JR, et al. Inclusion body myositis and myopathies. Ann Neurol. 1995;38(5):705–13.
19. Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Michelants H. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006;54(8):2665–73.
20. Sontheimer RD. Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis sine myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness? J Am Acad Dermatol. 2002;46(4):626–36.
21. Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet. 2003;362(9388):971–82.
22. van der Meulen MF, Bronner IM, Hoogendijk JE, Burger H, van Venrooj WJ, Voskuyl AE, et al. Polymyositis: an overdiagnosed entity. Neurology. 2003;61(3):316–21.
23. Bradley WG. Polymyositis: an overdiagnosed entity. Neurology. 2004;63(2):402. author reply 3
24. Hengstman GJ, van Engelen BG. Polymyositis: an overdiagnosed entity. Neurology. 2004;63(2):402–3. author reply 3
25. Miller FW, Rider LG, Plotz PH, Rutkove SB, Pestrunk A, Wortmann RL, et al. Polymyositis: an overdiagnosed entity. Neurology. 2004;63(2):402; author reply 3–3.
26. Amato AA, Griggs RC. Unicorns, dragons, polymyositis, and other mythological beasts. Neurology. 2003;61(3):288–9.
27. Hoogendijk JE, Amato AA, Lecky BR, Choy EH, Lundberg IE, Rose MR, et al. 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis. 10–12 October 2003, Naarden, The Netherlands. Neuromusc Disord. 2004;14(5):337–45.
28. Karpati G, Pouliot Y, Carpenter S. Expression of immunoreactive major histocompatibility complex products in human skeletal muscles. Ann Neurol. 1988;23(1):64–72.
29. Emself-Smith AM, Arahata K, Engel AG. Major histocompatibility complex class I antigen expression, immunolocalization of interferon subtypes, and T cell-mediated cytotoxicity in myopathies. Hum Pathol. 1989;20(3):224–31.
30. Pestrunk A. Acquired immune and inflammatory myopathies: pathologic classification. Curr Opin Rheumatol. 2011;23(6):595–604.
31. Musset L, Allenbach Y, Benveniste O, Boyer O, Bossuyt X, Bentow C, et al. Anti-HMGCR antibodies as a biomarker for...
immune-mediated necrotizing myopathies: a history of statins and experience from a large international multi-center study. Autoimmun Rev. 2016;15(10):983–93.

32. Christopher-Stine L, Casciola-Rosen LA, Hong G, Chung T, Corse AM, Mamman AL. A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy. Arthritis Rheum. 2010;62(9):2757–66.

33. Targoff IN, Mamyrrova G, Trieu EP, Perurena O, Koneru B, O’Hanlon TP, et al. A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum. 2006;54(11):3682–9.

34. Betteridge Z, McHugh N. Myositis-specific autoantibodies: an important tool to support diagnosis of myositis. J Intern Med. 2016;280(1):8–23.

35. Fujimoto M, Watanabe R, Ishitsuka O, Okiyama N. Recent advances in dermatomyositis-specific autoantibodies. Curr Opin Rheumatol. 2016;28(6):636–44.

36. Gunawardena H. The clinical features of myositis-associated autoantibodies: a review. Clin Rev Allergy Immunol. 2017;52(1):45–57.

37. Troyanov Y, Targoff IN, Tremblay JL, Gouet JR, Raymond Y, Senechal JL. Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients. Medicine (Baltimore). 2005;84(4):231–49.

38. Fernández C, Bardín N, De Paula AM, Salort-Campana E, Benyamine A, Franques J, et al. Correlation of cliniceroserologic and pathologic classifications of inflammatory myopathies: study of 178 cases and guidelines for diagnosis. Medicine (Baltimore). 2013;92(1):15–24.

Further expand a clinico-serological approach considering overlap features and autoantibodies as core components.

39. Troyanov Y, Targoff IN, Payette MP, Raynauld JP, Chartier S, Gouet JR, et al. Redefining dermatomyositis: a description of new diagnostic criteria that differentiate pure dermatomyositis from overlap myositis with dermatomyositis features. Medicine (Baltimore). 2014;93(24):318–32. Further expand a clinico-serological approach considering overlap features and autoantibodies as core components.

40. Senechal JL, Raynauld JP, Troyanov Y, Editorial: a new classification of adult autoimmune myositis. Arthritis Rheum. 2017;69(5):878–84.

41. Linklater H, Pipitone N, Rose MR, Norwood F, Campbell R, Salvarani C, et al. Classifying idiopathic inflammatory myopathies: comparing the performance of six existing criteria. Clin Exp Rheumatol. 2013;31(5):767–9.

42. Brady S, Squier W, Sewry C, Hanna M, Hilton-Jones D, Holton JL. A retrospective cohort study identifying the principal pathological features useful in the diagnosis of inclusion body myositis. BMJ Open. 2014;4(4):e004552. Comprehensive review of sIBM clinical features and the evolution of sIBM diagnostic criteria.

43. Lloyd TE, Mamman AL, Amato AA, Weiss MD, Needham M, Greenberg SA. Evaluation and construction of diagnostic criteria for inclusion body myositis. Neurology. 2014;83(5):426–33.

44. Hilton-Jones D, Brady S. Diagnostic criteria for inclusion body myositis. J Intern Med. 2016;280(1):52–62.

45. Mahler M, Miller FW, Fritzer M. Idiopathic inflammatory myopathies and the anti-synthetase syndrome: a systematic review. Autoimmun Rev. 2014;13(4–5):367–71.

46. Lega JC, Fabien N, Reynaud Q, Durieu I, Dutertre S, et al. The clinical phenotype associated with myositis-specific and associated autoantibodies: a meta-analysis revisiting the so-called anti-synthetase syndrome. Autoimmun Rev. 2014;13(9):883–91.

47. Trallero-Araguás E, Grau-Junyet JM, Labirupa-Itraburu A, Garcia-Hernandez FJ, Monteagudo-Jimenez M, Fraile-Rodriguez G, et al. Clinical manifestations and long-term outcome of anti-Jo1 antisyntethetase patients in a large cohort of spains patients from the GEAS-IIM group. Semin Arthritis Rheum. 2016;46(2):225–31.

48. Aggarwal R, Cassidy E, Fertig N, Koontz DC, Lucas M, Ascherman DP, et al. Patients with non-Jo-1 anti-tRNA-synthetase autoantibodies have worse survival than Jo-1 positive patients. Ann Rheum Dis. 2014;73(1):227–32.

49. Shi J, Li S, Yang H, Zhang Y, Peng Q, Lu X, et al. Clinical profiles and prognosis of patients with distinct antisynthetase autoantibodies. J Rheumatol. 2017;44(7):1051–7.

50. Rider LG, Werth VP, Huber AM, Alexanderson H, Rao AP, Ruperto N. Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: Physician and Parent/Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)/Childhood Health Assessment Questionnaire (C-HAQ), Childhood Myositis Assessment Scale (CMAS), Myositis Disease Activity Assessment Tool (MDAAT), Disease Activity Score (DAS), Short Form 36 (SF-36), Child Health Questionnaire (CHQ), physician global damage, Myositis Damage Index (MDI), Quantitative Muscle Testing (QMT), Myositis Functional Index-2 (FI-2), Myositis Activities Profile (MAP), Inclusion Body Myositis Functional Rating Scale (IBMFRS), Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI), Cutaneous Assessment Tool (CAT), Dermatomyositis Skin Severity Index (DSSI), Skindex, and Dermatology Life Quality Index (DLQI). Arthritis Care Res (Hoboken). 2011;63(Suppl 11):S118–57. Large cross-sectional study confirming the increased mortality risk in IIM-related ILD.

51. Andersson H, Kirkhus E, Garen T, Walle-Hanssen R, Merkell O, Molberg O. Comparative analyses of muscle MRI and muscular function in anti-synthetase syndrome patients and matched controls: a cross-sectional study. Arthritis Res Ther. 2017;19(1):17. Cross-sectional analyses of antisynthetase patients compared with healthy controls suggesting a complementary role for MRI in IIM assessment.

52. Van De Vlekkert J, Maas M, Hoogendijk JE, De Visser M, Van Schaik IN. Combining MRI and muscle biopsy improves diagnostic accuracy in subacute-onset idiopathic inflammatory myopathy. Muscle Nerve. 2015;51(2):253–8. Muscle MRI followed by muscle biopsies were performed on patients with subacute IIM onset. The authors found muscle MRI to be a useful diagnostic tool and guide for biopsy site selection.

53. Day J, Patel S, Limaye V. The role of magnetic resonance imaging techniques in evaluation and management of the idiopathic inflammatory myopathies. Semin Arthritis Rheum. 2017;46(5):642–9.

54. Cavazzana I, Fredi M, Ceribelli A, Mordenti C, Ferrari F, Carabellone N, et al. Testing for myositis specific autoantibodies: comparison between line blot and immunoprecipitation assays in 57 myositis sera. J Immunol Methods. 2016;433:1–5.

55. Bertolazzi C, Cutolo M, Smith V, Gutierrez M. State of the art on anti-Jo1 antibodies as core components.

56. Isenberg DA, Allen E, Farewell V, Ehrenstein MR, Hanna MG, Lundberg IE, et al. International consensus outcome measures for patients with idiopathic inflammatory myopathies. Semin Arthritis Rheum. 2017;47:432–44.

57. Isenberg DA, Allen E, Farewell V, Ehrenstein MR, Hanna MG, Lundberg IE, et al. International consensus outcome measures for patients with idiopathic inflammatory myopathies. Semin Arthritis Rheum. 2017;47:432–44.

58. Recently published clinical response criteria in adult IIM. Riders LG, Rider LG, Ruperto N, Bayat N, Emman B, Feldman BM, et al. 2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis: an International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Arthritis Rheumatol. 2017;69(5):911–23. Recently published clinical response criteria in juvenile DM.

59. Aggarwal R, Rider LG, Rider LG, Ruperto N, Bayat N, Emman B, Feldman BM, et al. 2016 American College of Rheumatology/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis: an International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Ann Rheum Dis. 2017;76(5):792–801. Recently published clinical response criteria in adult IIM.